Background Endothelial dysfunction has been identified as an etiologic factor for osteonecrosis of the femoral head (ONFH) and major adverse cardiovascular and cerebrovascular events (defined as major cardiovascular disease [CVD] and cerebrovascular accident [CVA]). However, the incidence of major adverse cardiovascular This study was supported by a grant (YHY) from Chang Gung Memorial Hospital, Chia-yi Branch. Each author certifies that his institution approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research. This work was performed in Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request. and cerebrovascular events in patients with nontraumatic ONFH and any association between the two diagnoses remain unclear. Questions/purposes We compared a large cohort of patients with nontraumatic ONFH and a matched control group without this diagnosis and (1) examined the frequency and hazard ratio (HR) of major adverse cardiovascular and cerebrovascular events in both groups adjusted for age, sex, socioeconomic status, and associated comorbidities (which we defined as the adjusted HR), (2) determined whether any association of ONFH and major adverse cardiovascular and cerebrovascular events was stable after adjusting for confounding variables, and (3) compared the occurrence of major adverse cardiovascular and cerebrovascular events with time in both groups. Methods A population-based cohort with a 14-year dataset period (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010) from the Taiwan National Health Insurance Research Database was used for this retrospective study. The database includes a greater than 99.5% Asian population randomly selected from more than 23 million citizens and foreigners residing in Taiwan for longer than 6 months. A total of 1562 patients with nontraumatic ONFH were identified from a population of one million patients in the database after excluding initially concomitant diagnoses of major CVD and CVA. The comparison group (n = 15,620) without ONFH was analyzed in a one-to-10 ratio by matching the study cohort based on age, sex, income, and urbanization. Results The patients with ONFH had a higher frequency of major adverse cardiovascular and cerebrovascular events than their counterparts without ONFH (19% versus 14%; p < 0.001). The patients with ONFH had 1.34-and 1.27-fold adjusted HRs for occurrence of major CVD and CVA as compared with the normal population (95% CI, p = 0.002, and 95% CI, p = 0.002, respectively). Sensitivity analysis showed a consistent association between ONFH and major adverse cardiovascular and cerebrovascular events after controlling for potentially relevant confounding variables such as hypertension and diabetes. After adjusting for potential confounders including surgery and medications, ONFH remained independently associated with major CVD (adjusted HR, 1.51, 95% CI 1.09-2.03, p = 0.026) and CVA (adjusted HR, 2.44, 95% CI 1.69-3.51, p < 0.001), apart from age older than 65 years and traditional atherosclerotic risk factors. The cumulative incidence of major adverse cardiovascular and cerebrovascular events also was higher in the ONFH group than the non-ONFH group (30.3% vs 23.1% at the end of followup, p < 0.001).
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Conclusions Patients with ONFH have a strong association with major adverse cardiovascular and cerebrovascular events as compared with the normal population, suggesting a potential common pathway involving endothelial dysfunction. In view of this association in the
Introduction
The etiology of osteonecrosis of the femoral head (ONFH) includes traumatic and nontraumatic factors [19] . Corticosteroid use and excessive alcohol consumption are believed to be etiologic in greater than 80% of patients with nontraumatic ONFH [5, 11] . Additionally, thrombophilia (hypercoagulability) has been suggested as a possible cause of idiopathic ONFH [21] . However, the exact pathogenesis remains unclear and is generally believed to be the result of genetic susceptibility, metabolic factors, and impedance of blood supply to the femoral head by (1) vascular damage, (2) increase in intraosseous pressure, (3) intravascular coagulation, or (4) mechanical stresses [4, 15, 19] . Growing evidence also suggests that endothelial cell or endothelial progenitor cell dysfunction associated with inadequate nitric oxide production may be considered one of the major contributors to ONFH [2, 7, 14, 23] . Therapeutic targets have focused on how to improve endothelial function, vasculogenesis, and the surrounding blood supply to the microvasculature of the femoral head [1, 3, 28] . It is recognized that endothelial cell dysfunction is a systemic vascular disorder that results in many traditional atherosclerotic risk factors such as hypertension, diabetes, and hyperlipidemia [8, 10, 20] . Additionally, an association between endothelial cell dysfunction and future major adverse cardiovascular and cerebrovascular events has been investigated [9, 10, 16] .
Given these relationships, we questioned whether there might be an association between major adverse cardiovascular and cerebrovascular events and ONFH. We theorized that patients with ONFH might have a greater incidence and risk of arterial thrombotic events such as those seen in major adverse cardiovascular and cerebrovascular events based on sharing a common mechanism of endothelial dysfunction.
We therefore sought to analyze the clinical association between these major adverse events and ONFH. We compared a large cohort of patients from the Taiwan National Health Insurance Research Database) [6] with nontraumatic ONFH and a matched control group without this diagnosis and (1) examined the frequency and hazard ratio (HR) of major adverse cardiovascular and cerebrovascular events in both groups adjusted for age, sex, socioeconomic status, and associated comorbidities (which we defined as the adjusted HR); (2) determined whether any association of ONFH and major adverse cardiovascular and cerebrovascular events was stable after adjusting for confounding variables, and (3) compared the occurrence of these major adverse events with time in both groups.
Materials and Methods
The National Health Insurance program in Taiwan provides health care to 99% of a population of 24,000,000 and links 97% of the hospitals and clinics in Taiwan (http:// nhird.nhri.org.tw/en/) [6] . Researchers can register and claim data of exactly one million individuals who have been systematically selected from all insured enrollees of the National Health Research Institute data bank in a randomized method. The database includes a greater than 99.5% Asian population randomly selected from more than 23 million citizens and foreigners residing in Taiwan for longer than 6 months. The National Health Research Institute dataset contains robust information regarding medical facilities, details of inpatient and outpatient orders, dental services, drug prescriptions, patient care provided by physicians, and the supplemental registration files (eg, payment, regions, and catastrophic illness) other than laboratory data. Diagnoses are entered based on the ICD-9, Clinical Modification (ICD-9-CM). In addition, the database contains all the pertinent health information of an individual insured enrollee, is representative of the Taiwanese population, and is used for Chinese populationbased research [6] .
This was a nationwide retrospective population-based cohort study. We selected patients with ONFH (ICD-9-CM code 733.42) in the National Health Research Institute data bank from January 1997 to December 2010. To identify patients with nontraumatic ONFH, patients with the concomitant diagnoses of femoral fracture (ICD-9-CM codes 820 and 821), dislocation of the hip (835), or an open wound of the hip and thigh (890) were excluded at the beginning of enrollment in our study. After further excluding (1) patients with followup less than 1 year; (2) missing data for baseline characteristics (only 0.09% of the database); (3) age younger than 18 years; and (4) concomitant diagnoses of acute myocardial infarction (acute myocardial infarction; ICD-9-CM codes 410-411), heart failure (428), and cerebrovascular accident (CVA; 430-436), a total of 1562 patients with nontraumatic ONFH were identified. The comparison cohort was drawn randomly from the same database, matching individuals without a history of ONFH by age, sex, income, and urbanization. Urbanization of the cities and counties was categorized in four levels (from Level 1 to Level 4 indicating the most to the least urbanized, respectively) and insurance taxable income level (expressed by New Taiwan dollars) was stratified in four classifications based on the monthly salary of the individual insured enrollee. The ratio of the non-ONFH group to the ONFH group of 10 to one was selected based on the prevalence of ONFH in Taiwan (approximately 1.5/1000) and therefore 15,620 patients without ONFH were allocated to the control group (Fig. 1) . This study was approved by the ethics institutional review board of Chang Gung Memorial Hospital (No. 201600594B1).
In both groups, 78% of patients were men and the median age was 47 years (interquartile range [IQR], 39-58 years). The majority (87%) of the patients were 65 years or younger. The frequencies of hypertension, diabetes, dyslipidemia, gout, systemic lupus erythematosus, peripheral vascular disease, and chronic kidney disease were higher in the ONFH group than the non-ONFH group. However, there was no difference in the frequency of atrial fibrillation and ischemic heart disease between the patients with and without ONFH. Up to 92% of patients with ONFH had Fig. 1 The flowchart shows how patients were enrolled and allocated to the ONFH and matched non-ONFH groups. AMI = acute myocardial infarction; HF = heart failure; CVA = cerebrovascular accident.
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Association of Cardiovascular and Cerebrovascular Events and Nontraumatic ONFH 867 a lower extremity surgical history; of these, 68% underwent at least one THA. More than 90% of patients with ONFH were prescribed NSAIDs (Table 1) . Major adverse cardiovascular and cerebrovascular events was defined as major cardiovascular disease (CVD) or CVA. Major CVD was defined as acute myocardial infarction (ICD-9-CM codes 410-411) or heart failure (428). Furthermore, CVA was defined as acute ischemic (433-436) or hemorrhagic stroke (430-432). Exposure to NSAIDs or systemic corticosteroid therapy (steroids) was defined as a regimen duration of 1 month or greater. Patients with nonexposure to NSAIDs or steroids were defined as those with no prescription for either medication or a regimen prescribed for less than 1 month. We considered short-term or temporary exposure to these medications as likely to have been for transient discomfort, rather than as part of any formal treatment regimen for ONFH, which likely would have entailed longer-term exposure to these drugs.
The diagnoses of ONFH and major adverse cardiovascular and cerebrovascular events (acute myocardial infarction, heart failure, and CVA) were confirmed by a consecutive minimum of three records of outpatient visits within 1 year or one diagnosis at the time of hospital admission during the study period. The date of the initial diagnosis was defined as the index date. We assessed preexisting comorbidities for each participant, including hypertension (ICD-9-CM codes 401-405), diabetes (250), dyslipidemia (272), gout (274), systemic lupus erythematosus (710.0), atrial fibrillation (427.31), chronic ischemic heart disease (412-414, 429.2), peripheral vascular disease (440, 443.9, 444.0, 444.2, 444.8, 444.9, 447.8, 447.9, 445.0, 445.02), chronic kidney disease (585), and obesity (278). We also examined the percentage of subjects in both groups who underwent procedures including surgery of the lower extremities (81.51, 81.52, 81.53, and 81.54) and THA (81.51). The information regarding medication use (NSAIDs and steroids) was acquired based on the Anatomical Therapeutic Chemical classification system from website of World Health Organization [29] .
Statistical Analysis
We compared the distribution of demographic factors and comorbidities between the study cohort (ie, ONFH) and the matched control cohort (ie, non-ONFH) with the independent t-test and chi-square test. The incidence and 95% CIs of major adverse cardiovascular and cerebrovascular events were calculated for the entire followup period. We used Kaplan-Meier analysis to estimate the cumulative incidence for major adverse cardiovascular and cerebrovascular events, including major CVD and CVA, at the end of the followup period and performed a log-rank test to examine differences between the groups.
Cox proportional hazard regression models were used to compute HRs and accompanying 95% CIs after adjusting for age, sex, surgery, and comorbidities. Different confounding variables were adjusted to investigate the risk of ONFH for occurrence of major adverse cardiovascular and cerebrovascular events. We also examined the outcomes (adjusted HR of ONFH for major CVD and CVA, respectively) stratified by subgroups according to sex, age, and comorbidities. Sensitivity analyses were conducted between ONFH and each of the comorbidities to assess whether the association between ONFH and outcome differed for patients with or without ONFH. Additionally, because the majority of patients with ONFH underwent lower extremity surgery and had been prescribed relevant medications, we adjusted procedures and medications apart from age, sex, urbanization and income, and traditional atherosclerotic risk factors (such as hypertension, diabetes, dyslipidemia, and gout) with multivariate Cox regression analysis to test the influences of procedure and medication on the development of major CVD and CVA. A two-tailed p value less than 0.05 was considered statistically significant. All the analyses were conducted using SAS ® Version 9.4statistical software (SAS Institute, Cary, NC, USA).
Results
Major adverse cardiovascular and cerebrovascular events were more common in patients with ONFH than in those without it, and the risk of having these adverse events develop remained greater in patients with ONFH than in controls even after adjusting for potential confounding variables such as age, sex, socioeconomic status, hypertension, and diabetes. At the end of followup, 292 of 1562 (19%) patients with ONFH had major adverse cardiovascular and cerebrovascular events develop, whereas a total of 2118 of 15,620 (14%) patients without ONFH had these adverse events develop (p < 0.0001; Table 1 ). The incidence of major CVD in patients with and without ONFH was 857 and 615 per 100,000 person-years, respectively. Thus, the incidence rate ratio of major CVD in ONFH to non-ONFH was 1.39 (95% CI, 1.16-1.68; p = 0.0005). After adjusting for age, sex, urbanization and income, and associated comorbidities, patients with ONFH had a 1.34-fold risk for future development of major CVD as compared with those without ONFH (95% CI, 1.11-1.61; p = 0.0021). Stratified analysis showed that the adjusted HR of major CVD in the ONFH to the non-ONFH group was higher in the subgroups of male sex, older age, and those without any comorbidities (Table 2 ). These findings suggest that in relatively healthy male patients older than 65 years, ONFH is independently associated with the risk of major CVD. Similarly, the adjusted HR of ONFH for CVA was 1.27 (95% CI, 1.09-1.47; p = 0.0017) after controlling for relevant confounding variables similar to those of major CVD. For relatively younger men 18 to 65 years old and those without any comorbidities, ONFH remained a risk factor for CVA occurrence ( Table 2) . The association between ONFH and major adverse cardiovascular and cerebrovascular events remained stable after controlling for major confounding factors plus any additional covariates; that is, the risk consistency remained in the model through a broad range of parameters in a sensitivity analysis. The risk of ONFH to be associated with either major CVD or CVA did not change after adjusting for different covariates such as dyslipidemia, systemic lupus erythematosus, and ischemic heart disease, suggesting the influence of ONFH on major adverse cardiovascular and cerebrovascular events was stable (Table 3) . After controlling for confounding variables like age, sex, socioeconomic background, comorbidities, surgical procedure, and medications, we found that patients older than 65 years with ONFH (adjusted HR, 1.51; 95% CI, 1.09-2.3) and traditional atherosclerotic risk factors were identified as the independent determinants for major CVD (all p values < 0.03). Older age and hypertension were the two most powerful risk factors for major CVD occurrence. After controlling for confounding variables, we found that age older than 65 years, ONFH (adjusted HR, 2.44; 95% CI, 1.69-3.51), and atherosclerotic risk factors were important determinants of the occurrence of CVA (all p values < 0.04). Hypertension, older age, and ONFH were identified as the three strongest risk factors for CVA. In contrast, surgery of the lower extremities and use of NSAIDs or steroids were not associated with major adverse cardiovascular and cerebrovascular events ( Table 4) .
The average followups of the ONFH and non-ONFH groups were 8.9 6 4.2 and 9.4 6 4.2 years, respectively. The occurrence of major adverse cardiovascular and cerebrovascular events increased steadily with time in both groups ( Fig. 2A) , and survivorship analysis showed that the cumulative incidence of major adverse cardiovascular and cerebrovascular events was higher in the ONFH group 2B) and CVA (Fig. 2C ) also showed a similar pattern to major adverse cardiovascular and cerebrovascular events regarding an increase in cumulative incidence between the ONFH and non-ONFH groups. The ONFH group had a higher cumulative incidence of major CVD (12.8% vs 10.6%, p < 0.001) and CVA (21.2% vs 17.1%, p < 0.001) than the non-ONFH group.
Discussion
With the potential common pathway of endothelial dysfunction, we sought to determine whether there was an association between ONFH and major adverse cardiovascular and cerebrovascular events using the Taiwan National Health Insurance Research Database [6] , an Asian population-based nationwide database including one million people randomly selected from more than 23 million residents in Taiwan. The most important findings of our study were that the risk of major adverse cardiovascular and cerebrovascular events was greater in patients with ONFH than in a matched population of individuals without ONFH, that this association was stable after controlling for relevant confounding variables such as age, sex, socioeconomic status, and comorbidities, and that the association persisted with time. Our findings suggest that effective clinical management of patients with ONFH should take into consideration not only the risk to these patients' hips, but also the potential for future occurrence of major adverse cardiovascular and cerebrovascular events in these relatively young patients. Our study has some obvious limitations. First, the Taiwan National Health Insurance Research Database does not contain detailed personal history and lifestyle information such as smoking or alcohol abuse, BMI, and functional capacity. We sought to overcome this limitation by matching age, sex, and socioeconomic background between study and comparison groups. Second, all the data in the current study have been registered with ICD-9-CM codes; therefore, further subclassification of disease status and determination of ONFH grades were impractical. However, the aim of our study was to investigate the association between ONFH and major adverse cardiovascular and cerebrovascular events, and therefore the disease severity should not have an obvious effect on outcomes. Third, laboratory data are not available in the Taiwan National Health Insurance Research Database. Fourth, we were unable to obtain information regarding other medications from the Taiwan National Health Insurance Research Database that were administered to the study or comparison cohorts because of research budget restrictions. Thus, the cardiovascular and cerebrovascular side effects from long-term use of NSAIDs, steroids, or alcohol could not be completely clarified in our study. In addition, whether the findings from this Chinese-based study can be applied to other ethnic populations will need further investigation. Furthermore, the causal relationship among endothelial dysfunction, ONFH, and major adverse cardiovascular and cerebrovascular events is complex and could not be clarified in a retrospective cohort study such as ours. Therefore, a prospective case-control or randomized trial might be conducted in the future to elucidate cause and effect. Finally, despite thrombophilia having been identified as one of the potential mechanism for ONFH [21] , we did not evaluate thrombophilia in this study as it is a major contributor to venous thromboembolism but not a causative factor for arterial cardiovascular events. In our study, not only was the frequency and incidence of major adverse cardiovascular and cerebrovascular events greater in patients with ONFH than in those without ONFH, but ONFH also was shown to be associated with the future occurrence of major adverse cardiovascular and cerebrovascular events. The link among endothelial cell dysfunction, arterial atherosclerosis, acute arterial occlusive syndrome, and an unfavorable prognostic outcome has been well established [8-10, 16, 20] . The underlying mechanisms of ONFH have been proposed to be multifactorial and multifaceted [4, 15, 19] . However, microvasculature damage or microenvironmental alternation in the bone marrow of the femoral head resulting from endothelial cell or endothelial progenitor cell dysfunction along with inadequate nitric oxide production [7, 13, 23] has been proposed to be the essential factor for the disturbance of femoral head blood supply, which, in turn, initiates the development of ONFH and propagates the disease. Such findings [7-10, 13, 16, 20, 23] may raise the question of whether the underlying mechanisms of ONFH and major adverse cardiovascular and cerebrovascular events are similar. Additionally, the current study showed that the relative risks of major CVD and CVA were notably higher in patients with ONFH than in those without ONFH. Intriguingly, an association between coronary heart disease and ONFH was identified by a previous study [12] . Our results are consistent with this finding and further support the concept that endothelial cell dysfunction may lie at the heart of ONFH and major adverse cardiovascular and cerebrovascular events. Because the increased risk of major adverse cardiovascular and cerebrovascular events in patients with ONFH could conceivably result from the higher frequency of relevant comorbidities, surgery, and associated medications in the ONFH group, we adjusted for different confounding variables with multivariate analysis to test for this possibility. The results showed that in addition to older age and hypertension, ONFH was also a risk factor for the occurrence of major CVD and CVA. This is another indication of the link between ONFH and major adverse cardiovascular and cerebrovascular events and further supports a rationale of endothelial dysfunction as a common pathologic mechanism [7, 13, 23] . Surprisingly, although surgery-associated vascular injury might induce subsequent endothelial dysfunction [18, 22] , our study revealed that surgery of the lower extremities was not associated with an increase in major CVD. Similarly, the concern that major adverse cardiovascular and cerebrovascular events might be associated with long-term use of NSAIDs [24, 27] or steroids [25, 26] was not observed in our study. According to the results from pooled groups of patients with ONFH and without ONFH, the effect of medication or surgery on major adverse cardiovascular and cerebrovascular events and the relationship between medication or surgery and major adverse cardiovascular and cerebrovascular events in the ONFH population currently remain unclear and need further investigation in the future.
Finally, we found that in patients between 18 and 65 years old, the association with CVA in the ONFH group was higher than in the non-ONFH group, whereas older (age > 65 years) patients with ONFH had a notably higher association with major CVD as compared with their counterparts without ONFH. Data from other studies [17, 19] have shown that ONFH usually affects people between 30 and 50 years old, and good surgical results can be achieved with total hip arthroplasty (THA) when indicated [19] . Therefore, findings from our study and these previous studies support that younger patients would be at risk for CVA and may require THA as early as possible. Our study further showed that surgery or medications used for ONFH did not increase the risk of major adverse cardiovascular and cerebrovascular events. Taken together, these findings further suggest that early awareness of the risk of major adverse cardiovascular and cerebrovascular events in ONFH and early therapeutic intervention are warranted in current clinical practice.
The results of this Taiwanese population-based study showed that patients with nontraumatic ONFH had a higher incidence and risk of major adverse cardiovascular and cerebrovascular events than the general population. ONFH had a greater than 1.3-fold risk for occurrence of major adverse cardiovascular and cerebrovascular events in our population. Based on the appearance of ONFH in a relatively young population and our findings of little to no risk of surgery or medication on the risk of major adverse cardiovascular and cerebrovascular events, we encourage clinicians to promptly recognize and manage ONFH. Additionally, potential therapeutic strategies aimed to improve endothelial dysfunction (eg, statin drugs) may deserve further investigation to reduce the risk of these major adverse events in patients with ONFH.
